Welcome to our dedicated page for Curaleaf Hldgs news (Ticker: CURLF), a resource for investors and traders seeking the latest updates and insights on Curaleaf Hldgs stock.
Curaleaf Holdings, Inc. reports developments across its consumer cannabis business, including retail dispensary openings, medical and adult-use product brands, quarterly operating results, and international expansion. The company trades on the Toronto Stock Exchange as CURA and on OTCQX as CURLF.
Recurring updates cover brands such as Curaleaf, Select, Grassroots, Find, Dark Heart, Anthem, and Four 20 Pharma; U.S. dispensary activity; medical cannabis distribution in Germany and other international markets; share repurchase activity; board and shareholder matters; and regulatory topics affecting cannabis operations.
Curaleaf (OTCQX:CURLF, TSX:CURA) confirmed its previously announced 1-for-3 reverse stock split of subordinate voting shares will be effective June 5, 2026. Shares will continue trading on the TSX as CURA with new CUSIP 23126M300.
Outstanding subordinate voting shares will decline from 698,731,895 to about 232,910,632, with fractional shares rounded to the nearest whole share. Multiple voting shares will be consolidated on the same 1‑for‑3 basis to preserve relative rights.
Curaleaf (OTCQX:CURLF) will implement a 1-for-3 reverse stock split of its subordinate voting shares, effective on or about June 5, 2026, following TSX conditional approval.
The split is intended to raise the share price, support potential U.S. exchange uplisting, and broaden institutional and retail investor access.
Curaleaf (OTCQX: CURLF) opened two new Florida medical dispensaries in Jacksonville Beach and Fernandina Beach on May 8, 2026, raising its Florida store count to 73 and nationwide total to 165.
The locations offer Curaleaf and partner brands including Reef, Grassroots, Dark Heart, Anthem pre-rolls, and the new Select Briq 2. Grand opening events run May 8–9 (Jacksonville Beach) and May 15–16 (Fernandina Beach) with promotions, giveaways, and patient offers.
Curaleaf (OTCQX: CURLF) reported Q1 2026 results: net revenue $324.2M (up 6% YoY), international revenue $47.2M (up 35% YoY), gross profit margin 49%, net income $70.1M and adjusted EBITDA $63.4M (19.6% margin). The company completed a buyout of Four20 Pharma to 100% ownership and closed $500M senior secured notes to refinance prior debt.
Cash was $106.1M, debt net $565.1M, and weighted average shares were 775.4M.
Curaleaf (OTCQX: CURLF) announced on May 1, 2026 the appointment of Torsten Greif to its Board of Directors. Greif is a founder of Four 20 Pharma, Curaleaf's German brand, and brings expertise in cannabis cultivation, regulatory strategy, and EU-GMP medical cannabis distribution as Curaleaf expands in Europe.
Curaleaf (OTCQX: CURLF) completed the buyout of the remaining 45% stake in Four 20 Pharma GmbH on April 30, 2026, making Four 20 a fully owned Curaleaf subsidiary.
Four 20 Pharma is EU-GMP and GDP licensed in Germany; the purchase strengthens Curaleaf's vertical, seed-to-patient supply chain and supports further European brand expansion.
Curaleaf (OTCQX: CURLF) will hold its Annual and Special Meeting on June 22, 2026 at 9:00 a.m. ET in a virtual format. Shareholders of record as of May 5, 2026 may vote.
Agenda items include director elections, auditor appointment, continuation of the 2018 LTIP, an MVS sunset amendment, an Option/RSU exchange (options tied to >=US$5.00), and the previously announced BC-to-Delaware continuation arrangement. A management information circular will be filed and mailed around May 12, 2026 via SEDAR+ and EDGAR. The company will use notice-and-access delivery for meeting materials.
Curaleaf (OTCQX: CURLF) announced a normal course issuer bid to repurchase up to 34,388,831 subordinate voting shares (approx. 5% outstanding) from April 20, 2026 through April 19, 2027, with an aggregate fair market value of about U.S.$83 million. Purchases will follow TSX rules, be made at market price, and any shares bought will be cancelled.
The program permits daily purchases up to 210,139 shares (25% of six‑month ADTV) and is expected to start after Curaleaf reports Q1 results for the period ended March 31, 2026.
Curaleaf (OTCQX: CURLF) announced that Chief Legal Officer Peter Clateman has extended an automatic securities disposition plan (ASDP), effective March 31, 2026, to allow orderly exercise of vested options expiring July 2027 and sale of shares to cover anticipated taxes.
Sales may begin on or about July 1, 2026 and continue for six months, will be executed by an independent broker at prevailing market prices, and were authorized before a blackout period with restrictions on amendment.
Curaleaf (OTCQX: CURLF; TSX: CURA) will report first quarter 2026 financial and operating results for the period ended March 31, 2026 after market close on May 5, 2026. Management will host a conference call and audio webcast that day at 5:00 p.m. ET with prepared remarks and Q&A.
Dial-in, passcode, and webcast details are provided for live participation; a replay will be available through May 12, 2026.